Previous 10 | Next 10 |
NeoGenomics remains insulated and differentiated from peers via a plethora of offerings in clinical diagnostics, as a potential market-leader in oncology services. The growth vision looks at consolidating a myriad of oncology diagnostics under one roof via clinical and pharmaceutical ...
FT. MYERS, FL / ACCESSWIRE / November 13, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Doug VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Fina...
National In-Home Blood Sample Collection Through ExamOne® and Metro Health Staffing, LLC FT MEYERS, FL / ACCESSWIRE / November 9, 2020 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, ann...
NeoGenomics, Inc. (NEO) Q3 2020 Results Earnings Conference Call October 27, 2020, 8:30 AM ET Company Participants Doug VanOort - Chairman and CEO Kathryn McKenzie - Chief Financial Officer Rob Shovlin - President, Clinical Services Division George Cardoza - President, Pharma Services Divisio...
Image source: The Motley Fool. Neogenomics Inc (NASDAQ: NEO) Q3 2020 Earnings Call Oct 27, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Neogenomics Inc (NEO) Q3 2020 Earnings Call Transcript
NeoGenomics ([[NEO]] -6.6%) reports Q3 consolidated revenue of $125M (+20% Y/Y), misses consensus by $0.79M.Bifurcating revenue: clinical services increased 17% to $109M and pharma services increased 38% to $17M.Pharma services backlog increased 57% to $185M...
NeoGenomics (NEO): Q3 Non-GAAP EPS of $0.06 beats by $0.02; GAAP EPS of $0.04 beats by $0.02.Revenue of $125.44M (+19.8% Y/Y) misses by $0.79M.Press Release For further details see: NeoGenomics EPS beats by $0.02, misses on revenue
Third-Quarter 2020 Results and Highlights: Consolidated revenue increased 20% to $125 million Clinical Services revenue increased 17% to $109 million Pharma Services revenue increased 38% to $17 million Pharma Services backlog increased 57% to $185 million FORT M...
NeoGenomics (NASDAQ:NEO) is scheduled to announce Q3 earnings results on Tuesday, October 27th, before market open.The consensus EPS Estimate is $0.04 (-42.9% Y/Y) and the consensus Revenue Estimate is $126.23M (+20.6% Y/Y).Over the last 2 years, NEO has beaten EPS estimates 88% of the time a...
NeoGenomics ([[NEO]] -0.6%) plans to open a state-of-the-art research laboratory by 2021 in China in association with the new lab PPD ([[PPD]] +0.1%) is opening in Suzhou.The NeoGenomics laboratory is expected to support Greater China-focused clinical trials and testing for global and local C...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...